LEXX

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT We update investors on Lexaria Bioscience Corporation’s (NASDAQ:LEXX) latest news on the occasion of the company’s report of fiscal year 2026 first quarter financial results for the period ending November 30th, 2025. During the first quarter, the company executed a capital raise, achieved several milestones for its GLP-1 agonist studies, and extended its Material Transfer Agreement with an undisclosed pharmaceutical company. Following the quarter end, Lexaria presented its Phase Ib results for study GLP-1-H24-4, emphasizing the material reduction in side effects for DehydraTECH (DHT)-formulated semaglutide. Since our previous report in late December, Lexaria has released an annual letter from the CEO, been awarded additional patents, and reported final results from human pilot study #5 (GLP-1-H25-5). CEO Richard Christopher summarized the key achievements and objectives for Lexaria in his letter, centering on the performance of the DHT-formulated GLP-1 agonists that have been evaluated in many preclinical and clinical studies over the last several years. The most important takeaways from this work have been the reduction in adverse events compared with the injected version of the diabetes and weight loss drugs, as well as confirming the products’ ability to improve glucose, insulin, and weight using the DHT formulation. Supporting these efforts is a portfolio of 60 DHT patents granted around the world, with the most recent wave emphasizing the delivery platform’s treatment of nicotine, hypertension, epilepsy, and diabetes. Fiscal Year 2026 First Quarter Results Lexaria reported fiscal year 2026 first quarter results for the three-month period ending November 30th, 2025, through the filing of its Form 10-Q. The company reported no revenues and total operating expense of $1.6 million, resulting in net loss of ($1.6) million or ($0.07) per diluted common share. For the quarter and versus the comparable prior year period: Revenue totaled $0 compared to $184,000 as the Premier arrangement expired at the end of the last fiscal year, and no B2B product revenues were recognized compared with revenues of $174,000 and $9,923; Research and development expenses totaled $671,000, down 66% from $2.0 million, reflecting the completion of GLP-1 agonist trials, including the Phase Ib GLP-1-H24-4 study; General and administrative expenses totaled $902,000, down 2% from $919,000 on account of reduced spending on advertising and promotions and lower consulting fees, partially offset by higher consulting fees and salaries, and greater legal and professional fees; Other loss of ($22,000) represented unrealized loss on marketable securities related to decreases in fair value and a small contribution from interest income; Net loss was ($1.6) million, or ($0.07) per share, compared to net loss of ($2.7) million or ($0.16) per share. As of November 30th, 2025, cash and marketable securities totaled $4.4 million, which compares to $1.8 million at the end of fiscal year 2025. Cash burn for 1Q:26 was approximately ($989,000). Cash from financing over the same period totaled $3.5 million from equity sales. Following the end of the quarter, Lexaria executed additional equity sales, raising a net $3.0 million. CEO Letter to Stakeholders CEO Richard Christopher celebrates his first full calendar year as Lexaria’s Chief Executive Officer and communicates the company’s 2025 achievements and future expectations in his annual letter. In 2025, Lexaria generated results for its #3, #4, #5, and biodistribution studies. Study #4 was a Phase Ib registrational study conducted in Australia, which we summarize later in this report, and study #5 examined DehydraTECH (DHT) liraglutide and is also reviewed. 10 additional patents were issued in 2025, and the company’s MTA was extended. 2025’s focus was almost exclusively upon evaluating the DHT technology with the three leading GLP-1 agonist drugs in the market: semaglutide, tirzepatide, and liraglutide. Mr. Christopher sets the stage in the weight loss space, citing 2025 growth for the GLP-1 agonist class of 51% in contrast to the performance of Rybelsus of just 2%. The company believes that it can make an impact on the growth of oral administration of these products with its technology that can limit gastrointestinal side effects. Lexaria is also advancing in other areas with its DHT technology, including cardiovascular disease, sleep apnea, metabolic dysfunction associated steatohepatitis (MASH/NASH), chronic kidney disease, and neurodegenerative diseases. New Patents The January 12th CEO letter publicized the issuance of 10 patents in 2025, bringing the company’s total to 56. Ten days later, on January 22nd, Lexaria announced the award of six additional patents since early October 2025 that span geographies from the US and Canada to Japan and Australia. These awards are in the following families: Compositions and Methods for Sublingual Delivery of Nicotine First patent in Australia granted Compositions and Methods for Treating Hypertension First European Union patent granted Compositions and Methods for Treating Epilepsy Two new Australian patents granted One new European Union patent granted Compositions and Methods for Treating Diabetes One new US patent Summary Lexaria reports its fiscal year first quarter 2026 results along with final results for the Human Pilot Study #5. CEO Christopher updates investors on his patent portfolio and communicates the next steps for the GLP-1 agonist program. We expect the team will increase its business development activity, leveraging its October arrangement with an advisory firm. We believe that the many biosimilar manufacturers of liraglutide will provide a fertile market eager to meet the demand for an oral formulation of the biologic for weight loss. The improved side effect profile for DHT-formulated GLP-1 agonists is a welcome feature that addresses one of the primary shortcomings of the existing offerings. We note that there are at least six biosimilar producers of liraglutide, each of which could be a prospective partner for Lexaria.[1] Post fiscal year end, Lexaria raised an additional $7.5 million gross that should fund the company for 2026. Now that Lexaria has additional data to share, we expect final disposition for the MTA and further conversations with partners that may lead to collaborations. DehydraTECH offers improved speed of onset, better bioavailability, reduced adverse events, and potentially a favorable regulatory pathway via the 505(b)(2) regulatory pathway. The reduced level of adverse events, especially GI tolerability, as shown in all of Lexaria’s human studies, is a particularly attractive feature. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. ________________________ [1] We identified liraglutide biosimilars manufactured by Lupin, Meitheal Pharmaceuticals, Teva, Sandoz and others including those from compound pharmacies.

Company Further Examining the Pursuit of the World's First Oral Liraglutide Product KELOWNA, BC / ACCESS Newswire / February 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce final results from Human Pilot Study #5 (GLP-1-H25-5) (the "Study"), which compared oral DehydraTECH-liraglutide ("DHT-LIR") capsules to injected Saxenda® branded liraglutide ("SAX-LIR"). "We are extremely pleased with the results of Human Pilot Study #5," stated Richard Christopher, CEO of Lexaria. "In addition to achieving the Study's primary safety and tolerability endpoint, we also demonstrated that oral DehydraTECH-liraglutide functioned comparably to traditionally injected liraglutide, consistent with our regulatory development pathway objectives," continued Mr. Christopher. "We now have compiled compelling evidence to further support examining the pursuit of the world's first oral liraglutide product." The primary results from this Study were issued on June 11, 2025, at which time Lexaria reported a 22.7% reduction in adverse events ("AEs") with DHT-LIR as compared to the SAX-LIR, with a particular emphasis on a 67% reduction in nausea and a 31% reduction in overall gastrointestinal AEs. The differences in measurements of blood glucose, insulin and body weight across most time points were not statistically significantly different, with remarkable similarity in many areas and slight differences in others. Weight loss was experienced by 9 out of 10 people in each Study arm and slightly higher in the Saxenda® Study arm; though weight loss was not a primary goal of this Study with the very short treatment period of only 1 week with each treatment. Evaluating the safety and tolerability of the oral DHT-LIR capsules relative to injected SAX-LIR was the primary endpoint of this Study. This objective was successfully met with clear signs of improved safety and tolerability performance by the DHT-LIR. Since mid-2025, Lexaria and its third-party bioanalytical service providers have invested considerable time and expertise in attempting to determine the precise pharmacokinetic ("PK") blood liraglutide quantitation and profiling results from the Study. This included the use of two different manufactured brands of commercially available ELISA (enzyme-linked immunosorbent assay) test kits. Throughout the course of this bioanalytical work, challenges were encountered with background signal noise detection, which complicated our ability to accurately capture blood liraglutide measurements in both the SAX-LIR and DHT-LIR study samples. The background signal noise is believed to be attributable to the fact that liraglutide and other peptide drugs are commonly known to bind with, and have poor separation from, albumin, a naturally occurring protein present in human blood plasma. In light of this issue, the PK testing from the Study was limited to exploratory visualization of the raw ELISA signals which, nonetheless, over time demonstrated broadly similar temporal patterns between the DHT-LIR and the SAX-LIR. The visualization of the similar signal patterns of the two treatments is consistent with the instances of functional comparability otherwise demonstrated in the Study, pursuant to Lexaria's regulatory development pathway objectives. Lexaria considers this to be particularly noteworthy given the fact that the DHT-LIR dose quantity studied was conservatively low (see "About the Study", below) for this initial human investigation, relative to that of the SAX-LIR, with room for possibly increasing the dose if necessary in potential future studies. The two most important strategic objectives of this Study were: In both these respects, the results from this Study have shown tremendous promise while also evidencing tolerability advantages from a user appeal perspective. Saxenda® is owned by Novo Nordisk, which also sells an oral tablet form of the blockbuster GLP-1 drug semaglutide under the brand name Rybelsus®. Of note, the salcaprozate sodium ("SNAC") delivery technology that Novo Nordisk acquired for $1.8 billion utilized within the Rybelsus® tablet was found by other researchers to be unfavorable for co-formulation of an oral version of liraglutide. Liraglutide went off patent in 2024 and is now offered in a generic injectable format by Teva Pharmaceuticals and others. For these reasons, Lexaria is excited about the possibility of establishing DehydraTECH-liraglutide as a brand-new oral liraglutide-dosing alternative to Saxenda® and the other generic versions of injected liraglutide. Lexaria feels this is an unmet market need which DehydraTECH may empower. Lexaria has had, and intends to continue, discussions with pharmaceutical companies regarding the possibility of collaborating in pursuing a 505(b)(2) Pathway to enable commercialization of an oral DHT-LIR product. Further details on prospective next steps in development of the DHT-LIR product candidate will be provided when available in due course. About the Study Study GLP-1-H25-5 was a pilot, cross-over investigation in 10 overweight (average weight 73 Kg; average body mass index 26.81) volunteers. SAX-LIR injection was administered daily at its commercially available starting dose of 0.6 mg for 7 days with a follow-up evaluation at day 8, compared to oral DHT-LIR (45 mg), also administered daily for 7 days with an identical day 8 evaluation. All drug administrations were performed after an overnight fast. Oral administration was accomplished with a 50 mL glass of water. Blood draws were performed upon the subjects at baseline (pre-dose) and multiple time points over the first 12 hours of day 1 of the Study, followed by daily draws 30-minutes post-dosing on each of days 2-7 of the Study and, finally, on day 8 without any dosing. Subjects were allowed to consume standardized meals/snacks over the 12 hours post-dosing on the first treatment day at predetermined time intervals. Subjects were allowed to resume their normal diet following fasted dosing on the subsequent treatment days. The DHT-LIR 45 mg dose equated to a 75-fold multiple of the 0.6 mg SAX-LIR dose exposure tested. This dosing multiple was selected conservatively relative to the 98- to 196-fold dosing multiple currently used with Novo Nordisk's Rybelsus®-branded semaglutide, whereby a 14 mg Rybelsus® daily dose is considered to be bioequivalent to a 0.5-1.0 mg once-weekly dose of its Ozempic®- or Wegovy®-branded semaglutide injectable products. Accordingly, Lexaria notes that there is arguably room to further titrate the DHT-LIR oral dose upwards in prospective future studies in an effort to most closely match the effectiveness of the injectable regimen consistent with its 505(b)(2) Pathway strategy. About Lexaria Bioscience Corp. & DehydraTECH DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 60 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com. CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. INVESTOR CONTACT: George Jurcic - Head of Investor Relations [email protected] Phone: 250-765-6424, ext. 202 SOURCE: Lexaria Bioscience Corp. View the original press release on ACCESS Newswire

Lexaria Bioscience (LEXX) provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH study arms relative to the Rybelsus control study arm. At week 16, rough parity was reached between the DHT arms and the Rybelsus control as there were no statistically significant treatment differences observed in terms of the numerical least squares means changes from baseline in the secondary efficacy parameters of mean fasting glucose, cholesterol, and low density lipoprotein cholesterol specifically. While both DHT-semaglutide and Rybelsus reduced body weight during the Study, it was noteworthy that upon a separate body composition analysis performed in the Study using the dual-energy, X-ray absorptiometry / Bioelectrical Impedance Analysis methodology, at week 12, the DHT-semaglutide arm showed a modest numerical LSM reduction in fat mass of -1.08 kg and in total mass of -1.40 kg, accompanied by minimal reduction in lean mass of -0.41 kg. In contrast, the Rybelsus control arm achieved greater LSM reductions in fat mass of -3.55 kg and in total mass of -5.36 kg, but also had a notably higher reduction in lean mass of -1.72 kg. This finding is considered intriguing as it possibly points to proportionally lower lean mass to fat mass bodyweight reduction potential being achievable with DHT-semaglutide. While blood pressure analysis was not formally an efficacy endpoint of the Study, it was noteworthy that the DHT-cannabidiol arm achieved meaningful reductions in blood pressure. This is of special interest since the Study participants were not generally hypertensive. At week 4, a mean change of -4.6 mmHg in systolic blood pressure and -4.0 mmHg in diastolic blood pressure was evidenced in the DHT-CBD arm. Blood pressure reductions were also evident in this arm following completion of treatment at the week 16 follow up point with a mean change of -2.6 mmHg in systolic blood pressure and -3.0 mmHg in diastolic blood pressure reported. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on LEXX: Disclaimer & DisclosureReport an Issue Lexaria Bioscience files to sell 2.75M shares of common stock for holders Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026 Lexaria Bioscience achieves primary endpoint in Phase 1b study GLP-1-H24-4 Lexaria Bioscience Secures $3.5 Million in Direct Offering to Boost R&D Lexaria Bioscience prices 2.66M share at the market offering at $1.315

KELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), recently completed in Australia, focusing on 4 DehydraTECH™ ("DHT") study arms relative to the Rybelsus® control study arm. "We are pleased to report additional data from our first Phase 1b clinical study," stated Richard Christopher, CEO of Lexaria. "It adds to a growing dataset which showcases the many potential benefits of our platform technology - DehydraTECH." "At our stage of development, clinical data is of paramount importance to us," continued Mr. Christopher. "Lexaria's "follow the science" approach and the positive results from this Study are already guiding our 2026 R&D plans as well as our business development initiatives. We are expecting exciting developments in 2026 and beyond." Secondary Efficacy Parameters At week 16, rough parity was reached between the DHT arms and the Rybelsus® control as there were no statistically significant treatment differences observed in terms of the numerical least squares means ("LSM") changes from baseline in the secondary efficacy parameters of mean fasting glucose, cholesterol, and low density lipoprotein ("LDL") cholesterol specifically (nominal p-values were >0.05). Body Composition While both DHT-semaglutide and Rybelsus® reduced body weight during the Study, it was noteworthy that upon a separate body composition analysis performed in the Study using the dual-energy, X-ray absorptiometry / Bioelectrical Impedance Analysis methodology, at week 12, the DHT‑semaglutide arm showed a modest numerical LSM reduction in fat mass of −1.08 kg and in total mass of −1.40 kg, accompanied by minimal reduction in lean mass of −0.41 kg. In contrast, the Rybelsus® control arm achieved greater LSM reductions in fat mass of −3.55 kg and in total mass of −5.36 kg, but also had a notably higher reduction in lean mass of −1.72 kg. This finding is considered intriguing as it possibly points to proportionally lower lean mass to fat mass bodyweight reduction potential being achievable with DHT-semaglutide (37.96% as compared to 48.45% for Rybelsus®). Blood Pressure Analyses While blood pressure analysis was not formally an efficacy endpoint of the Study, it was noteworthy that the DHT-cannabidiol ("DHT-CBD") arm achieved meaningful reductions in blood pressure. This is of special interest since the Study participants were not generally hypertensive (i.e., hypertension was not a recruitment requirement in this Study). At week 4, a mean change of −4.6 mmHg in systolic blood pressure and −4.0 mmHg in diastolic blood pressure was evidenced in the DHT-CBD arm. Blood pressure reductions were also evident in this arm following completion of treatment at the week 16 follow up point (4 weeks after cessation of treatment) with a mean change of −2.6 mmHg in systolic blood pressure and −3.0 mmHg in diastolic blood pressure reported. These findings are very encouraging relative to Lexaria's separate program interests in pursuing development of DHT-CBD for the treatment of hypertensive patients. Lexaria has earlier received FDA clearance to conduct a Phase 1b study to investigate this phenomenon more thoroughly. Pharmacokinetic Exploratory Analyses Blood plasma level analyses of CBD, semaglutide and tirzepatide were performed for all patients as applicable using a validated liquid chromatography mass spectrometry ("LCMS") assay. In the DHT‑CBD alone and DHT‑CBD with DHT‑semaglutide arms, plasma CBD concentrations were quantifiable through week 16. In the DHT-tirzepatide arm, plasma tirzepatide concentrations were quantifiable only through week 12, with the maximum plasma concentrations observed at week 8. Plasma semaglutide concentrations were not quantifiable in the DHT-semaglutide and DHT-CBD with DHT-semaglutide arms. This was believed to be due to unforeseen LCMS assay issues affecting blood plasma recovery and detection for DHT-delivered semaglutide, not applicable to the Rybelsus® delivered semaglutide. However, preliminary testing using a separately performed, enzyme-linked immunosorbent assay ("ELISA") upon a subset of patient blood plasma samples from these DHT arms did detect clearly recoverable/measurable semaglutide levels. Based on this, additional testing is in process on the full complement of patient blood plasma samples from these arms. Short Form 36 Health Survey The short form 36 health survey ("SF-36") is a widely administered questionnaire designed to allow persons to self-report their perceived health status assessing health-related quality of life parameters across eight domains (i.e., physical/role functioning, bodily pain, general health, vitality, mental health, social functioning). In this Study, participants were asked to complete the SF-36 upon the completion of dosing. Those participants in the Rybelsus® control Study arm reported modest mean improvements ranging from 2.39 to 4.35 points or no changes (neither worsening nor improving); whereas those participants receiving the DHT-semaglutide arm reported mean improvements of >5 points in the physical components and >3 points in the mental components. It is not known specifically why the DHT-semaglutide participants self-reported better SF-36 survey results than the Rybelsus®-only participants, but it may be at least in part linked to the reduction in adverse events ("AE's"), as noted in our December 23, 2025 press release. Overall Conclusions and Next Steps As previously announced, study GLP-1-H24-4 met its primary endpoint objectives showing good safety and tolerability of all DHT test articles with clear reductions in total and gastrointestinal ("GI")-specific AEs relative to the Rybelsus® control arm. The Study demonstrated positive findings across numerous parameters with comparability, and in some instances, superiority to the Rybelsus® control arm. Shareholders and interested parties should note that the final and complete Study report is in excess of 7,000 pages long. When Lexaria communicates that a great deal of information must be reviewed prior to this public dissemination or via partner review, the enormity of this data set should always be considered. Based on the findings from this Study, Lexaria considers the DHT-semaglutide test article to be most worthy of continued investigation for the therapeutic indication studied. However, it would seem most prudent for any such work to include the salcaprozate sodium ("SNAC") ingredient chemistry present in Lexaria's DHT-semaglutide formulations originally tested in its previous human clinical studies GLP-1-H24-1 and GLP-1-H24-2, (Human Pilot Studies #1 and #2), but not included in the current Study. These previous human clinical studies evidenced the strongest DHT-semaglutide efficacy performance superior to the Rybelsus® control used therein, while also maintaining improvements in safety and tolerability relatively speaking with the DHT-semaglutide formulation studied. Moving forward, Lexaria intends to consider its options to perform prospective follow on human clinical testing with a DHT + SNAC + semaglutide composition compared to Rybelsus® accordingly, to expand and build upon the learnings in aggregate from studies GLP-1-H24-1, GLP-1-H24-2 and GLP-1-H24-4. Details will be provided on this if/when Lexaria formalizes plans to perform such a study. In parallel, now that public release of final results from study GLP-1-H24-4 has occurred, Lexaria is taking steps to proceed with relaying the dataset to the pharmaceutical company ("PharmaCo") that Lexaria has a Material Transfer Agreement ("MTA") in place with. As previously announced, this MTA was recently extended through April 30, 2026 to accommodate time needed for PharmaCo's receipt and review of this dataset, after which time further information will be provided. Lexaria remains hopeful that achievement of its primary endpoint in the current Study, with DHT evidencing superior safety and tolerability and a significant reduction in GI side effects especially relative to Rybelsus®, will be considered attractive and compelling to PharmaCo in its deliberations about potential next steps in its relationship with Lexaria. This would be consistent with the pharmaceutical industry's strong appetite in the related therapeutic sectors for improvements in unwanted side effects as Lexaria previously reported. Lexaria was pleased to have recently raised additional capital through financings intended to allow it to fund prospective new development opportunities through the entirety of calendar 2026; the details of which are in the process of being finalized and will be forthcoming in due course. Deployment of these funds may include, but not be limited to, progressing its prospective further human clinical testing upon DHT + SNAC + semaglutide as noted above, as well as supporting other complementary research and development program work in the Glucagon-Like Peptide-1 ("GLP-1") sector. About the Study Study GLP-1-H24-4 investigated 126 overweight, obese, pre-diabetic and/or type-2 diabetic human volunteers/patients. The primary endpoint in this study was to assess impacts upon safety and tolerability based on the incidence of treatment emergent adverse events. This Study initially included 3 DHT arms testing DHT-CBD, DHT-semaglutide and a combination of DHT-CBD with DHT-semaglutide. Performance across these three initial study arms was monitored compared to commercially available Rybelsus® as the Study positive control group. Of note, the DHT-semaglutide composition evaluated used pure semaglutide processed without inclusion of the SNAC ingredient found in the Rybelsus® composition differing, therefore, from the DHT-semaglutide composition previously tested by Lexaria in its studies GLP-1-H24-1 and GLP-1-H24-2 that used reformulated commercially available SNAC-inclusive Rybelsus® as the semaglutide active substance input. In addition, this Study was expanded after initiation to incorporate an orally delivered DHT-tirzepatide arm to assess safety, tolerability and effectiveness in an effort to potentially advance the findings discovered with Lexaria's previous DHT-tirzepatide human pilot study GLP-1-H24-3. Of note, however, the DHT-tirzepatide composition evaluated in study GLP-1-H24-4 used pure tirzepatide as the active substance input instead of reformulated commercially available Zepbound® differing, therefore, compared to the composition utilized in study GLP-1-H24-3. About Lexaria Bioscience Corp. & DehydraTECH DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with over 50 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com. CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. INVESTOR CONTACT: George Jurcic - Head of Investor Relations [email protected] Phone: 250-765-6424, ext 202 SOURCE: Lexaria Bioscience Corp. View the original press release on ACCESS Newswire

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT As we step into fall, Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably, it reported the last patient-last visit for the Phase Ib study designated GLP-1-H24-4 and reported data from its rodent biodistribution study. It also closed a $4.0 million capital raise earlier this week. Activity in the obesity and GLP-1 agonist space has been robust in 2025 with a number of deals and new trial data announced. In this report we will bring investors up to date on recent activity and update near term milestones. Lexaria View on GLP-1 Agonists In the fall of 2023, Lexaria began its efforts to evaluate members of the GLP-1 agonist class formulated with DehydraTECH to determine if the new formulation could improve bioavailability, cost-effectiveness, tolerability, weight-loss potential, management of diabetes and other health conditions. Since then, the company has launched five human studies along with other non-human work to answer this question. Over the last two years, Lexaria has reported the data from these trials showing reduced levels of side effects, comparable levels of glucose reduction and insulin increase, less semaglutide necessary than in Rybelsus to achieve similar effects. In an August 6th press release, management penned a missive reviewing GLP-1 agonist market activity highlighting the primary players (Eli Lilly and Novo Nordisk), the number of drugs in development (39) and number of sponsors advancing them (34). The note from management also addressed the dealmaking environment around the class, underlining the collaboration between Novo Nordisk and Septerna, Roche’s asset acquisition from Zealand Pharma, Regeneron’s licensing deal with Hansoh Pharmaceuticals and Merck and Cyprumed, which we discussed in our previous report. In late August, Eli Lilly announced data from its Phase III trial evaluating its oral GLP-1 receptor agonist, orforglipron. The study met all of its primary and secondary endpoints. With the completion of the study, Lilly has all the clinical data necessary to submit orforglipron for approval globally. Availability of an oral for Eli Lilly could raise the stakes for having an oral version of this class of drug and benefit Lexaria as others find other oral solutions for GLP-1 agonist delivery. Lexaria’s data comparing Rybelsus, tirzepatide, semaglutide and liraglutide with DHT-formulated versions of these compounds now spans five human studies. With this trove of supportive information, the company seeks the interest of a major player in the industry who recognizes the value of an oral version of these injectable drugs. GLP-1 Agonist Rodent Biodistribution Study In November 2024, Lexaria announced that it had signed a contract for a GLP-1 agonist biodistribution study with an unidentified contract research organization. The research fluorescently tagged DHT formulated semaglutide and tracked its biodistribution in rodents. Understanding the distribution of the drug in subject tissue will help researchers understand the binding properties and receptors that are targeted by the drug. It can also help understand in which areas or tissues the drug concentrates and potentially lead to unwanted side effects. The work will also help researchers understand how orally delivered DHT-semaglutide differs from the infused formulation of the drug. Last month, Lexaria announced results from this study in a press release. Study Design Details were tracked via fluorescent imaging detection to show how and where the semaglutide distributes and localizes following oral ingestion by Sprague-Dawley rats. After the initial evaluation, the animals were euthanized and various key tissues were examined including those from the brain, pancreas, lung, kidney, liver and heart for more detailed fluorescent imaging detection showing very specific tissue localization patterns and concentrations. The analysis includes DHT and non-DHT formulated Rybelsus orally administered product. Efforts also included measurement of certain GLP-1 receptor specific antibodies detectable through an immunofluorescence methodology. This was done to allow the analytical laboratory to confirm the extent of GLP-1 receptor binding of the two formulations in the tissue samples taken from the animals, providing a detailed measure of fluorescence distribution and localization patterns. The fluorescent tagging of the two variations of semaglutide (Rybelsus and the DHT formulation) will show the biodistribution differences between the two. Study Results A September 19th press release shared results from the study. It noted that DHT-fluorescently tagged semaglutide (FTS) demonstrated a predominantly higher apparent trend in brain biodistribution than the Rybelsus equivalent composition and all study controls. The determination was made based on fluorescent signal intensity using whole brain imaging. Below, the DHT performance can be seen in the middle light blue, aqua and turquoise bars in the center of the exhibit. Following the whole-organ imaging of the rat model, the brain was further sectioned via sagittal slices (2-3 mm thickness) into two and then four pieces to better visualize the brain regions in which semaglutide is binding and stimulating a response. These regions of interest include the brainstem, known for direct semaglutide interaction; the paraventricular nucleus of the hypothalamus, involved in energy homeostasis; and the circumventricular organs, which lack a blood-brain barrier, such as the area postrema, subfornical organ and median eminence. Upon measurement, investigators noted that all three DHT doses tested displayed fluorescence above that of the naïve and vehicle groups, while only the highest dosage (15mg/kg) of the Rybelsus equivalent composition surpassed the naïve and vehicle groups. Lexaria believes that findings from the study suggest that the DHT-FTS composition, absent all of the Rybelsus composition excipients, may enable unique delivery and distribution enhancements in brain tissue possibly supporting improved pharmacodynamic performance. Complementary biodistribution benefits may be derived by using a similar DehydraTECH semaglutide composition combined with the Rybelsus excipients. Future testing to show this would be required to measure this and potential safety and efficacy improvements. This type of study helps researchers further understand the pharmacokinetics and mechanism of action of DHT-formulated semaglutide and will be part of the conversations with large pharma partners. GLP-1-H24-4 Interim Results (Fourth Study) At the end of July, Lexaria provided an interim look into its GLP-1-H24-4 study highlighting the reduction in side effects for the DHT formulated GLP-1s vs. approved versions of the drug. At eight weeks, the DHT-semaglutide arm saw a 36.5% reduction in overall side effects and 43.5% lower gastrointestinal (GI) side effects compared to results in the Rybelsus arm. Our report reviewing 3Q:25 results provided a summary of adverse events from the trial. Lexaria’s press release documented at least one adverse event (AE) for each of the 25 subjects in the Rybelsus arm. Five subjects in the DHT arm (5/24) experienced no AEs (referenced as a 20.8% reduction in Lexaria’s press release). A study cited by Lexaria (Bergmann, et al. 2022) found just under 90% of semaglutide patients in the study experienced an AE. The press release compares this to DHT-semaglutide’s AE rate of 79.2%. However, the comparison must be placed in the context of the Lexaria data at the 8-week mark and including 24 people compared to the greater than 1,000 subjects assessed for injected semaglutide. Lexaria reviewed several tirzepatide studies and found a similar incidence of AEs as they did for semaglutide in a meta-analysis (Mishra et al. 2023). The study noted a positive correlation between dose level and incidence of AEs. Another remarkable takeaway from the meta-analysis is the high rate of GI-related AEs which comprised up to 50% of the total AEs for injectable tirzepatide. Lexaria compared this hurdle to the 22% rate achieved with DHT-semaglutide in the 8-week study. GLP-1-H24-4 was conducted with 24-25 overweight, obese, pre- or type 2 diabetic patients in each of the five study arms (n=126), of which 4 arms evaluated various DehydraTECH formulations with the 5th being the Study control arm. Arm 1 evaluated DHT-CBD, Arm 2, DHT-semaglutide and Arm 3, DHT-semaglutide and DHT-CBD. Arm 4 evaluated Rybelsus tablets and Arm 5 examined DHT-tirzepatide. Changes in glycated hemoglobin (HbA1c) and weight were other measured endpoints in the GLP-1-H24-4 study. Lexaria extracted these same metrics from Novo Nordisk’s Pioneer studies[2],[3]. DHT-semaglutide was able to reduce HbA1c and weight over the eight weeks, but at a lesser magnitude than what was achieved by Rybelsus. While DHT-semaglutide achieved lower levels of weight loss and HbA1c reduction compared to Rybelsus, it also is associated with reduced side effects, especially those that are GI-related. We think that 8-week data is insufficient for making significant comparisons. The primary takeaways are that the trend in endpoints is moving in the right direction and that reduced adverse events will allow for a greater number of patients to continue on a therapy so they can obtain its benefit. Lexaria also brought attention to the focus on adverse events with a quote[4] from Martin Hoist Lange, who was promoted to Chief Scientific Officer of Novo Nordisk earlier this week: “We want to win the weight loss [battle] but we also want to have a gastrointestinal adverse event profile that is attractive and competitive.” On August 14th, 2025 Lexaria announced that the last patient-last visit had been completed. Study work accelerates with full sample and data analyses underway with the goal of reporting data prior to the end of 2025. The company’s CRO is managing the laboratory analysis phase of the work and management is blinded until the work has been completed. $4.0 Million Offering On September 26th, Lexaria announced a $4.0 million registered direct offering priced at the market. 2,666,667 shares of Lexaria common stock were offered at $1.50 per share along with the same number of warrants with a $1.37 exercise price. Gross proceeds are estimated to be approximately $4.0 million and we forecast net proceeds to be about $3.6 million after deducting the placement agent fees and other offering expenses. The offering closed on September 29th. Pipeline SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. ________________________ [1] Total radiant efficiency (TRE) is a measure of the summation of flux (i.e., measured fluorescence) within a given tissue region of interest (ROI). For the brain analyses in this study, an ROI was drawn around the excised brain tissue samples to quantify the total fluorescence within that region in each case. To account for the variability in ROI size, the TRE was divided by the area of the ROI to "normalize" the value. In short, Normalized TRE = TRE/ROI area. [2] Aroda, V.R. et al. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders. October 2022. [3] Husain, M. et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. June 2019. [4] Novo Nordisk R&D Investor Event, June 22, 2025

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal third quarter 2025 results via the filing of its Form 10-Q. Since our previous quarterly report at the end of April, the company has provided an update on its Material Transfer Agreement, attended BIO, completed the GLP-1-H25-5 study and reached a milestone of 50 patents granted worldwide. The company also compiled key safety data from its GLP-1-H24-4 study supporting the favorable safety and tolerability profile of DehydraTECH (DHT) -formulated GLP-1 agonists. In this report we will bring investors up to date on recent activity and review third quarter financial performance. Third Quarter 2025 Results Lexaria filed its Form 10-Q reporting quarterly results for the three-month period ending May 31st, 2025. The company reported revenues of $174,000 and total operating expense of $3.8 million resulting in net loss of ($3.8) million or ($0.21) per diluted common share. For its fiscal third quarter and versus the comparable prior year period: Revenue totaled $174,000, up 107% from $84,000 due to increases in licensing revenues related to the agreement with Premier; Research and development expenses totaled $2.7 million, up 370% from $0.6 million as a result of increased expenses related to the Phase Ib GLP-1 agonist trial and investigational drug product manufacturing; General and administrative expenses totaled $1.2 million down 4% from $1.3 million due to lower accounting and professional fees; Interest income was essentially $0 in both periods; Other loss of ($40,000) represented unrealized loss on marketable securities related to decreases in fair value; Net loss was ($3.8) million, or ($0.21) per share, compared to net loss of ($1.8) million or ($0.13) per share. As of May 31st, 2025, cash and marketable securities totaled $4.6 million which compares to $6.6 million at the end of fiscal year 2024. Cash burn for the first nine months of FY:25 was approximately ($7.9) million. Cash from financing over the same period totaled $6.0 million from equity sales. Management estimates that the company holds sufficient cash to meet its financial obligations until second quarter 2026. Cyprumed Partnership Deal activity has picked up in recent months with almost 90 transactions taking place year to date. We see this as a good sign as established biopharmaceutical companies contend with their patent cliffs and look to new technologies to achieve growth. One deal stands out to us with relevance to Lexaria that took place between Merck & Co. and Cyprumed GmbH. In the arrangement, Merck gains a license and option to develop oral formulations of its peptides using Cyprumed’s drug delivery technology. Cyprumed will be eligible to receive $493 million in upfront, development, regulatory and net sales milestones associated with the approval of any products under the collaboration. Notably, Cyprumed has not conducted clinical trials and has demonstrated oral bioavailability of up to 70% in rodents, dogs and non-human primates. Cyprumed is developing technology platforms for the oral administration of therapeutic peptides, including GLP-1 analogues, macrocycles and mini-proteins. Its proprietary delivery platforms feature tablet formulations that offer superior oral bioavailability and build on already approved pharmaceutical excipients. Cyprumed’s objective is to provide easy to manufacture, patient-friendly oral dosage forms of peptide therapeutics. Peptide therapeutics are one of the fastest-growing drug classes, but most are still administered parenterally due to GI tract limitations such as low pH, proteases, mucus and tight epithelia. Cyprumed uses pH-programmable enteric layers for precise timing of delivery. We see this deal as promising for Lexaria which has shown clinical evidence of safety and efficacy of oral delivery of peptides including liraglutide, semaglutide and tirzepatide. As the focus of next generation GLP-1 agonists shifts towards improving the safety profile, we see a place for DehydraTECH in the pantheon of drug delivery technologies. GLP-1-H25-4 Interim Results (Fourth Study) Lexaria provided an interim look into its GLP-1-H25-4 study highlighting the reduction in side effects for the DHT formulated GLP-1s with the approved versions of the drug. At eight weeks, the DHT-semaglutide arm saw a 36.5% reduction in overall side effects and 43.5% lower gastrointestinal side effects compared to results in the Rybelsus arm. Below is a summary of the adverse event (AE) profile for the study. Lexaria’s press release documented at least one AE for each of the 25 subjects in the Rybelsus arm. Five subjects in the DHT arm (5/24) experienced no AEs (referenced as a 20.8% reduction in Lexaria’s press release). A study cited by Lexaria (Bergmann, et al. 2022) found just under 90% of semaglutide patients in the study experienced an AE. The press release compares this to DHT-semaglutide’s AE rate of 79.2%. However, the comparison must be placed in the context of the Lexaria data at the 8-week mark and including 24 people compared to the n of >1,000 for injected semaglutide. Lexaria reviewed several tirzepatide studies and found a similar incidence of AEs as they did for semaglutide in a meta-analysis (Mishra et al. 2023). The study noted a positive correlation between dose level and incidence of AEs. Another remarkable takeaway from the meta-analysis is the high rate of gastrointestinal (GI) -related AEs which comprised up to 50% of the total AEs for injectable tirzepatide. Lexaria compared this hurdle to the 22% rate achieved with DHT-semaglutide in the 8-week study. Changes in glycated hemoglobin (HbA1c) and weight were other measured endpoints in the GLP-1-H24-4 study. Lexaria extracted these same metrics from Novo Nordisk’s Pioneer studies[1],[2]. DHT-semaglutide was able to reduce HbA1c and weight over the eight weeks, but at a lesser magnitude than what was achieved by Rybelsus. While DHT-semaglutide achieved lower levels of weight loss and HbA1c reduction compared to Rybelsus, it also is associated with reduced side effects, especially gastrointestinal ones. We think that 8-week data is insufficient for making significant comparisons. The primary takeaways are that the trend in endpoints is moving in the right direction and that reduced adverse events will allow for a greater number of patients to continue on a therapy so they can obtain its benefit. Lexaria also brought attention to the focus on adverse events with a quote[3] from Martin Hoist Lange, who was promoted to Chief Scientific Officer of Novo Nordisk earlier this week: “We want to win the weight loss [battle] but we also want to have a gastrointestinal adverse event profile that is attractive and competitive.” GLP-1-H25-5 Completion and Safety Data (Fifth Study) Lexaria received independent review board (IRB) approval in January, clearing the start of its Human GLP-1 Study #5 (GLP-1-H25-5). It compared an oral version of liraglutide (Saxenda) formulated from the DHT processing of liraglutide (DHT-liraglutide) to the conventional injected liraglutide. This study was instigated by the successful results in the liraglutide 12-week rodent study which read out in November 2024. DHT-liraglutide reduced weight and blood sugar at levels exceeding the performance of comparator Rybelsus. On April 2nd, Lexaria announced that it had begun dosing patients in study #5. Lexaria completed its GLP-1-H25-5 study in June and reported initial safety data. GLP-1-H25-5 was a pilot, cross-over investigation of 10 overweight volunteers administered oral DehydraTECH-liraglutide and Saxenda (injected liraglutide). The study had two objectives to determine if: GLP-1 Agonist Work Over the last two years, Lexaria has evaluated the three leading Glucagon-Like Peptide-1 (GLP-1) agonists that are widely used for treating diabetes and weight loss. This includes liraglutide in the study referenced above as well as semaglutide and tirzepatide, which were evaluated in the GLP-1-H24-4 and GLP-1-H24-3 studies. With seven preclinical and clinical studies evaluating DHT, Lexaria has demonstrated improved performance from the technology and is seeking an established pharmaceutical partner to fund further clinical trials. The partnership would support a filing of a new drug application (NDA) leading to approval of a GLP-1 agonist-DHT oral formulation. GLP-1-H25-5 Safety Data In its June 11th press release, Lexaria provided adverse event (AE) safety data for the DHT and Saxenda arms of the trial. To place the data in context, it is necessary to understand the source of the AEs. A blood draw was required to evaluate drug performance and safety according to the trial protocol. Four AEs related to the blood draw in the DHT arm and one AE in the Saxenda arm were recorded. Since the blood draw was related to the trial and not the administration and effect of the drug, we exclude the blood draw-related AEs in the next paragraph’s safety comparison. Ignoring the blood draw’s impact, the DHT arm produced 17 AEs compared to 22 in the Saxenda arm. This shows a 22.7% lower relative incidence of AEs.[4] Specifically, nausea was 67% lower and gastrointestinal events were 31% lower in patients administered the DHT formulation. There were no statistically significant differences in blood glucose, insulin, and body weight across most time points between the two arms. Weight loss was achieved by 9 of 10 subjects with the magnitude of weight loss characterized as “slightly higher” in the Saxenda study arm. However, weight loss was not a primary goal of this short-duration study. The small sample size prevents the study from generating statistically significant results and readers should be cautious in overestimating the reliability of the findings. However, in context with the other studies run, these results provide additional confidence of the improved tolerability of the DHT formulation. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. ________________________ [1] Aroda, V.R. et al. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders. October 2022. [2] Husain, M. et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. June 2019. [3]Novo Nordisk R&D Investor Event, June 22, 2025 [4] Including the AEs related to the peripheral intravenous line used for blood sampling, DHT produced 21 AEs while Saxenda produced 23.

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus® DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus® DehydraTECH-GLP-1 study arms evidencing patient safety and tolerability consistent with the primary study endpoint KELOWNA, BC / ACCESS Newswire / July 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following partial 8-week positive interim results update on the phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), currently underway in Australia, focusing on the DehydraTECH ("DHT") glucagon-like peptide-1 ("GLP-1") study arms 2 and 5 relative to the Rybelsus® control study arm 4. "We are extremely encouraged by the interim results received to date aligned with our primary study endpoint," said Richard Christopher, CEO of Lexaria. "DehydraTECH is continuing to demonstrate obvious superiority in reducing unwanted side effects compared to the world's only approved oral-based GLP-1 medication, Rybelsus®." Adverse Events After 8 weeks of treatment, Lexaria's DehydraTECH-GLP-1 arms are tracking very nicely from a safety and tolerability perspective relative to the Rybelsus® control arm; most notably in terms of reductions in the incidence of gastrointestinal ("GI") adverse events ("AEs"): n = number of patients included in each study group for safety and tolerability assessments Of note, every person taking Rybelsus® in the Study experienced at least one AE. There was a 20.8% reduction in the overall number of persons experiencing an AE with DehydraTECH-semaglutide ("DHT-semaglutide") vs. Rybelsus® and a 36.5% reduction in the total quantity of AEs derived from DHT-semaglutide vs. Rybelsus®. There was also a 43.5% reduction in GI AEs from persons taking DHT-semaglutide vs. Rybelsus®. In Novo Nordisk's® Semaglutide Treatment Effect in People with obesity (STEP) studies, across a patient population of 3,331 people, 2,934 or 88.1% of them experienced AEs of any kind. Through 8 weeks, only 79.2% of patients in the DHT-semaglutide study arm have experienced AEs of any kind, meaning 10.1% fewer patients in the DHT-semaglutide study arm experienced AEs relatively speaking. Potentially removing all AEs from 10% of a patient population that is currently millions of people, could provide immense relief for many and encourage more people to continue on their treatment protocol without premature discontinuation as is often a challenge commercially today due to unwanted AEs. It is difficult to compare the DehydraTECH-tirzepatide ("DHT-tirzepatide") AEs to any benchmark because there is no commercially available orally-dosed tirzepatide sold today, as tirzepatide is sold by Eli Lilly only in injectable formats. A meta-analysis reviewing 10 different injected tirzepatide trials involving 6,836 patients found broadly similar incidences of AEs as did the Lexaria Study examining orally dosed DHT-tirzepatide, but that meta-analysis noted that 40% to 50% of injected tirzepatide AEs were GI-related, whereas for the DHT-tirzepatide study arm that proportion of GI-related AEs through 8 weeks is much lower at 22%. This could potentially signify that oral DHT-tirzepatide might reduce AEs by as much as half, compared to the injectable tirzepatide that was evaluated in those earlier studies. HbA1c and Bodyweight Assessments of the magnitude of decreases in glycated haemoglobin ("HbA1c"), as a primary blood test for blood sugar levels, and body weight are the major efficacy endpoints of the Study. For comparison purposes, in Novo Nordisk's® Pioneer 1 phase 3a randomized study conducted in 703 patients with type 2 diabetes, daily doses of Rybelsus® semaglutide were administered at varying dose levels, and, after 26 weeks of dosing, the average changes in HbA1c levels and body weight were reported as follows: Further, Novo Nordisk's® Pioneer 6 phase 3a randomized study conducted in 1,591 patients received daily doses of Rybelsus® administered at 3 mg for the first 4 weeks; 7 mg for the next 4 weeks; and 14 mg thereafter until the conclusion of the study. As such the Pioneer 6 study utilized a dose escalation strategy nearly identical to the Lexaria Study for the first 8 weeks thereof at least, with average results shown in the table below: **8-week results from Pioneer 6 study have been extrapolated from the study appendix In the context of this press release it is very important to remember that Lexaria is, today, only reporting interim average 8-week results which is clearly a small fraction of the time studied relative to the above noted Pioneer 1, 26-week study, therefore making Lexaria's Study results more relatable to the Pioneer 6, 8-week study interim results data: n = number of patients included in each study group for HbA1c and body weight efficacy assessments Lexaria's average DHT-semaglutide weight loss results after 8 weeks are tracking similar to the historical performance of Rybelsus® in the much larger Pioneer studies, which is thus far encouraging to see. Curiously, the Rybelsus® body weight performance data in the current Lexaria Study appears to be much stronger than the results shown above in both the 26-week Pioneer 1 study and in the Pioneer 6, 8-week interim data. The reasons for this apparent anomaly are presently unknown, but likely related to the small sample size of the Lexaria Study. The historical studies conducted in thousands of persons are more likely to be representative of real-world performance. For HbA1c levels it is important to understand that HbA1c measures blood glucose over a 8-12 week period of time, thus the current 8-week data from Lexaria's Study is barely relevant compared to expected 12-week data. Furthermore, there is no statistically significant difference between the DHT-semaglutide and Rybelsus® reductions in HbA1c witnessed at the 8-week point thus far in the Study (p=0.069). The 12-week HbA1c data should be more representative, and potentially, quite different from the 8-week data. Additional 8-week interim Study data may or may not be released as it is more fully processed and understood in the weeks to come. The vast majority of laboratory-derived data, including a battery of additional safety, tolerability and efficacy parameter assessments beyond those summarized here, and all final results will not be available until near the end of calendar-2025. The Study is currently approaching the "last patient last visit" milestone and remains on schedule. About Lexaria Bioscience Corp. & DehydraTECH DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com. CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. INVESTOR CONTACT: George Jurcic - Head of Investor Relations [email protected] Phone: 250-765-6424, ext 202 SOURCE: Lexaria Bioscience Corp. View the original press release on ACCESS Newswire